Samstein, Robert M. http://orcid.org/0000-0001-6860-2401
Krishna, Chirag
Ma, Xiaoxiao http://orcid.org/0000-0001-8661-5660
Pei, Xin
Lee, Ken-Wing
Makarov, Vladimir
Kuo, Fengshen http://orcid.org/0000-0003-1797-2896
Chung, Jonathan
Srivastava, Raghvendra M.
Purohit, Tanaya A.
Hoen, Douglas R.
Mandal, Rajarsi
Setton, Jeremy
Wu, Wei
Shah, Rachna
Qeriqi, Besnik
Chang, Qing
Kendall, Sviatoslav
Braunstein, Lior
Weigelt, Britta
Blecua Carrillo Albornoz, Pedro http://orcid.org/0000-0002-1012-0300
Morris, Luc G. T. http://orcid.org/0000-0002-4417-2280
Mandelker, Diana L.
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
de Stanchina, Elisa
Powell, Simon N.
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Riaz, Nadeem http://orcid.org/0000-0001-9873-5862
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP5-OD028171)
Burroughs Wellcome Fund
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 OD020355, R35 CA232097)
Pershing Square Foundation
EIF | Stand Up To Cancer
Article History
Received: 4 August 2019
Accepted: 2 October 2020
First Online: 16 November 2020
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity, holds equity in An2H and acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. L.G.T.M. receives research funding from AstraZeneca. T.A.C. has served as an advisor for Bristol-Myers Squibb, Illumina, Eisai and An2H. MSK has licensed the use of TMB for the identification of patients who benefit from immune checkpoint therapy to PGDx. MSK, R.M.S., L.G.T.M. and T.A.C. receive royalties as part of this licensing agreement. J.S.R.-F. reports personal/ consultancy fees from Goldman Sachs and membership of the advisory boards of VolitionRx, Page.AI, Invicro, Roche, Genentech and Ventana, outside the submitted work. N.R. has received research funding from BMS, Pfizer and REPARE Therapeutics and has served as an ad hoc consultant to Illumina, REPARE Therapeutics and Mirati Therapeutics.